Vitex Inactine Surgery Study On Schedule Despite Suspension Of Chronic Trial
This article was originally published in The Gray Sheet
Executive Summary
Vitex expects to complete a Phase III trial of its Inactine pathogen inactivation system for red blood cells used during surgery by 2005, even though the firm has halted a separate Phase III study in chronic transfusions